58 related articles for article (PubMed ID: 18288134)
1. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
2. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
[TBL] [Abstract][Full Text] [Related]
3. Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
Tsilimidos G; Blum S
Ann Hematol; 2023 Sep; 102(9):2619-2620. PubMed ID: 37256305
[No Abstract] [Full Text] [Related]
4. JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
Tosoni L; Fabbro D; Pizzano U; Mullai R; Morelli G; Franzoni A; Damante G; Toffoletti E; Damiani D; Fanin R; Tiribelli M
Ann Hematol; 2023 May; 102(5):1279-1280. PubMed ID: 36947213
[No Abstract] [Full Text] [Related]
5. Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation.
Shen HX; Huang XQ; Fan CQ; Cao YX; Zhao H; Duan JG
Chin Med J (Engl); 2021 May; 134(10):1251-1253. PubMed ID: 33941751
[No Abstract] [Full Text] [Related]
6. EnvIRONment modifies polycythemia vera.
Prchal JT; Reeves BN
Blood; 2023 Apr; 141(17):2042-2044. PubMed ID: 37103951
[No Abstract] [Full Text] [Related]
7. Pediatric chronic myeloid leukemia P190 variant with IgA vasculitis: Rare association-case report.
Shah K; Murugasamy S; Appaji L; Kumar A; Kumar N; Kaushik PS; Reddy M; Thumallapalli A; Aruna Kumari BS
Pediatr Blood Cancer; 2024 Jan; 71(1):e30755. PubMed ID: 37908041
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Rambaldi A; Iurlo A; Vannucchi AM; Noble R; von Bubnoff N; Guarini A; Martino B; Pezzutto A; Carli G; De Muro M; Luciani S; McMullin MF; Cambier N; Marolleau JP; Mesa RA; Tibes R; Pancrazzi A; Gesullo F; Bettica P; Manzoni S; Di Tollo S
Leukemia; 2020 Aug; 34(8):2234-2237. PubMed ID: 32047238
[No Abstract] [Full Text] [Related]
9. Engineering a humanized animal model of polycythemia vera with minimal
Parsons TM; Krishnan A; Dunuwille WMB; Young AL; Arand J; Han W; Challen GA
Haematologica; 2024 Mar; 109(3):968-973. PubMed ID: 37767551
[No Abstract] [Full Text] [Related]
10. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
Hochman MJ; Smith BD; Karantanos T; Braunstein EM; Gojo I; Jain T; Streiff MB; Moliterno AR; DeZern AE
Int J Hematol; 2023 Mar; 117(3):456-462. PubMed ID: 36181657
[TBL] [Abstract][Full Text] [Related]
12. Emergence of
Lorenzo M; Grille S; Stevenazzi M
J Hematol; 2020 Apr; 9(1-2):23-29. PubMed ID: 32362982
[TBL] [Abstract][Full Text] [Related]
13. Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.
Liu C; Hu R; Du Z; Abecasis M; Wang C
Medicine (Baltimore); 2020 Jan; 99(5):e18811. PubMed ID: 32000382
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of
Yi JH; Kim HR
Blood Res; 2019 Mar; 54(1):77-79. PubMed ID: 30956968
[No Abstract] [Full Text] [Related]
15. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
Bader G; Dreiling B
J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
17. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A; Knoche EM; Engle EK; Fisher DA; Oh ST
Blood Cancer J; 2015 Oct; 5(10):e351. PubMed ID: 26430722
[No Abstract] [Full Text] [Related]
18. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Cornea MI; Levrat E; Pugin P; Betticher DC
J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.
Qin YW; Yang YN; Li S; Wang C
Indian J Hematol Blood Transfus; 2014 Sep; 30(Suppl 1):331-4. PubMed ID: 25332611
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
